PDCD1 and glioblastoma: Single-agent anti-PD-1 was not effective in patients with recurrent GBM who received prior chemotherapy and corticosteroids (~40% of patients at baseline were on prednisone at doses <10 mg, probably reduced for ‘trial eligibility’ in CheckMate 143) (refs. 12,28).